Long‐term efficacy and safety of oxycodone‐naloxone prolonged‐release formulation (up to 180/90 mg daily) – results of the open‐label extension phase of a phase III multicenter, multiple‐dose, randomized, controlled study

BACKGROUND: The inclusion of naloxone with oxycodone in a fixed combination prolonged‐release formulation (OXN PR) improves bowel function compared with oxycodone (Oxy) alone without compromising analgesic efficacy. In a recent 5‐week, randomized, double‐blind comparative trial of OXN PR and OxyPR,...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Eur J Pain
Auteurs principaux: Dupoiron, D., Stachowiak, A., Loewenstein, O., Ellery, A., Kremers, W., Bosse, B., Hopp, M.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2017
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5655918/
https://ncbi.nlm.nih.gov/pubmed/28474460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejp.1050
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires